No, acamprosate is NOT metabolized by the kidneys—it is EXCRETED unchanged by the kidneys without undergoing any metabolism.
Metabolism and Excretion Profile
Acamprosate undergoes zero metabolism. The drug is eliminated entirely unchanged from the body, with the kidneys serving as the primary route of excretion 1. This distinguishes acamprosate from many other medications used in alcohol use disorder treatment.
Key Pharmacokinetic Points:
- No hepatic metabolism: Acamprosate is not metabolized by the liver or any other organ system 2, 1
- Renal excretion: Following oral administration, the major route of excretion is via the kidneys as unchanged acamprosate 1
- Approximately 50% urinary excretion: Half of the elimination occurs as unchanged acetyl-homotaurine in urine; the other half may be eliminated by biliary excretion 3
- No cytochrome P450 involvement: Acamprosate does not interact with CYP1A2, 2C9, 2C19, 2D6, 2E1, or 3A4 systems 1
Clinical Implications for Renal Impairment
Because acamprosate is entirely dependent on renal excretion without metabolism, renal function directly determines drug clearance and plasma concentrations 1:
Dose Adjustments Required:
Moderate renal impairment (CrCl 30-50 mL/min): Reduce dose to 333 mg three times daily 1
- Peak concentrations are approximately 2-fold higher than in patients with normal renal function
- Elimination half-life is 1.8-fold longer
Severe renal impairment (CrCl ≤30 mL/min): Contraindicated 1
- Peak concentrations are approximately 4-fold higher
- Elimination half-life is 2.6-fold longer
- Linear relationship exists between creatinine clearance and total apparent plasma clearance
Mechanism of Renal Excretion:
Recent research has identified that acamprosate is a substrate of the human organic anion transporter 1 (OAT1), which facilitates its renal secretion 4. This active transport mechanism explains why acamprosate clearance exceeds glomerular filtration alone.
Advantages in Liver Disease
This lack of hepatic metabolism makes acamprosate particularly advantageous for patients with alcohol-associated liver disease 2:
- No hepatotoxicity concerns reported 2
- Pharmacokinetics unaltered in mild to moderate hepatic impairment (Child-Pugh A and B) 1
- No dose adjustment needed for liver dysfunction 1
- Emerging evidence suggests safety even in cirrhotic patients 5, 6
Contrast with Other AUD Medications:
Unlike naltrexone and disulfiram, which undergo hepatic metabolism and can cause liver damage, acamprosate's renal-only elimination pathway makes it the preferred option when hepatic function is compromised 2.
Common Pitfall to Avoid
Do not confuse "renal excretion" with "renal metabolism." The kidneys eliminate acamprosate through filtration and active tubular secretion (via OAT1), but they do not metabolize or chemically transform the drug. The compound exits the body in exactly the same chemical form as it entered 1, 3, 4.